Pharmaceutical

top of page

WSE_logo_artwork-rgb_outline_dark green.png

Genmab Rises as AbbVie Cancer Trial Opens Growth Opportunity

Genmab Rises as AbbVie Cancer Trial Opens Growth Opportunity

Genmab Rises as AbbVie Cancer Trial Opens Growth Opportunity

2 days ago1 min read

Shionogi Bets $2 Billion on a US Rare-Disease Drugmaker

Shionogi Bets $2 Billion on a US Rare-Disease Drugmaker

Shionogi Bets $2 Billion on a US Rare-Disease Drugmaker

Pharma Investments

4 days ago1 min read

Eli Lilly’s Next Obesity Drug Raises the Bar Again

Eli Lilly’s Next Obesity Drug Raises the Bar Again

Eli Lilly’s Next Obesity Drug Raises the Bar Again

Oct 11 min read

AstraZeneca Seeks US Approval for Lung Cancer Drug Combination

AstraZeneca Seeks US Approval for Lung Cancer Drug Combination

AstraZeneca Seeks US Approval for Lung Cancer Drug Combination

Oct 11 min read

Roche Wins New US Approval for Gazyva

Roche Wins New US Approval for Gazyva

Roche Wins New US Approval for Gazyva

Oct 11 min read

ADARx Raises $446 Million as Biotech IPOs Regain Momentum

ADARx Raises $446 Million as Biotech IPOs Regain Momentum

ADARx Raises $446 Million as Biotech IPOs Regain Momentum

Sep 281 min read

Genentech Makes a $1.5 Billion Bet on AI-Designed Cancer Drugs

Genentech Makes a $1.5 Billion Bet on AI-Designed Cancer Drugs

Genentech Makes a $1.5 Billion Bet on AI-Designed Cancer Drugs

Sep 281 min read

Viking’s Weight-Loss Drug Has a New Selling Point: Fewer Injections

Viking’s Weight-Loss Drug Has a New Selling Point: Fewer Injections

Viking’s Weight-Loss Drug Has a New Selling Point: Fewer Injections

Sep 242 min read

Grail’s Cancer Test Faces Its Most Important Question Yet

Grail’s Cancer Test Faces Its Most Important Question Yet

Grail’s Cancer Test Faces Its Most Important Question Yet

Sep 241 min read

Novo Nordisk’s $23 Billion Growth Plan Fails to Reassure Investors

Novo Nordisk’s $23 Billion Growth Plan Fails to Reassure Investors

Novo Nordisk’s $23 Billion Growth Plan Fails to Reassure Investors

Pharma Investments

Sep 212 min read

MapLight’s Schizophrenia Drug Worked, but Can It Compete?

MapLight’s Schizophrenia Drug Worked, but Can It Compete?

MapLight’s Schizophrenia Drug Worked, but Can It Compete?

Sep 162 min read

GSK’s Cancer Comeback Just Passed Another Important Test

GSK’s Cancer Comeback Just Passed Another Important Test

GSK’s Cancer Comeback Just Passed Another Important Test

Sep 153 min read

Eli Lilly's Next Obesity Drug Could Raise the Bar Again

Eli Lilly's Next Obesity Drug Could Raise the Bar Again

Eli Lilly's Next Obesity Drug Could Raise the Bar Again

Sep 142 min read

Tempus Isn't Just Buying a Cancer Testing Company, It's Buying an AI Advantage

Tempus Isn't Just Buying a Cancer Testing Company, It's Buying an AI Advantage

Tempus Isn't Just Buying a Cancer Testing Company, It's Buying an AI Advantage

Sep 142 min read

The AI Drug Revolution Is Finally Facing Its Biggest Test

The AI Drug Revolution Is Finally Facing Its Biggest Test

The AI Drug Revolution Is Finally Facing Its Biggest Test

Sep 142 min read

2

bottom of page